Escorting N-803 to the TME by altering tumor permissiveness or by adding a tumor-targeting component such as αPD-L1 to N-803 may further improve anti-tumor efficacy through in-situ activation of NK and CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.